This protocol screens antiviral candidates against Zika virus in cells, highlighting drug activity and toxicity.
The following is a protocol for live virus antiviral screening against Zika in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against Zika. You may choose to omit PgP inhibitor. Each live virus screening assay is accompanied by a matching cytotoxicity screening assay to investigate drug toxicity.
No takes yet. Share an insight, caveat, or question.
Briana L McGovern (2024) studied this question.